Prism Medico and Pharmacy Limited
Prism Medico and Pharmacy Limited (PRISMMEDI.BO) Stock Competitors & Peer Comparison
See (PRISMMEDI.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRISMMEDI.BO | ₹20.53 | +0.00% | 136.9M | -322.57 | -₹0.07 | N/A |
| BAJAJFINSV.NS | ₹2,033.20 | +0.00% | 3.3T | 34.33 | ₹59.96 | +0.05% |
| BAJAJFINSV.BO | ₹2,033.60 | +0.00% | 3.3T | 34.30 | ₹59.99 | +0.05% |
| ABCAPITAL.BO | ₹344.15 | +0.00% | 903.5B | 25.97 | ₹13.29 | N/A |
| ABCAPITAL.NS | ₹344.30 | +0.00% | 902.7B | 26.01 | ₹13.26 | N/A |
| AIIL.BO | ₹507.30 | +0.00% | 429.6B | 11.82 | ₹42.81 | +0.30% |
| PEL.BO | ₹1,124.60 | +0.25% | 254.9B | 44.24 | ₹25.42 | +0.98% |
| INDIGRID-IV.NS | ₹164.29 | +0.00% | 156.5B | N/A | N/A | +9.80% |
| INDIGRID.NS | ₹164.29 | +14.92% | 118.7B | 42.20 | ₹3.37 | +8.51% |
| ELCIDIN.BO | ₹111,200.65 | +0.00% | 22B | 16.93 | ₹6,505.79 | +0.02% |
Stock Comparison
PRISMMEDI.BO vs BAJAJFINSV.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, BAJAJFINSV.NS has a market cap of 3.3T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while BAJAJFINSV.NS trades at ₹2,033.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas BAJAJFINSV.NS's P/E ratio is 34.33. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to BAJAJFINSV.NS's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to BAJAJFINSV.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BAJAJFINSV.NS's competition here
PRISMMEDI.BO vs BAJAJFINSV.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, BAJAJFINSV.BO has a market cap of 3.3T. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while BAJAJFINSV.BO trades at ₹2,033.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas BAJAJFINSV.BO's P/E ratio is 34.30. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to BAJAJFINSV.BO's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to BAJAJFINSV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BAJAJFINSV.BO's competition here
PRISMMEDI.BO vs ABCAPITAL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ABCAPITAL.BO has a market cap of 903.5B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ABCAPITAL.BO trades at ₹344.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ABCAPITAL.BO's P/E ratio is 25.97. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ABCAPITAL.BO's ROE of +0.11%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ABCAPITAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABCAPITAL.BO's competition here
PRISMMEDI.BO vs ABCAPITAL.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ABCAPITAL.NS has a market cap of 902.7B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ABCAPITAL.NS trades at ₹344.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ABCAPITAL.NS's P/E ratio is 26.01. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ABCAPITAL.NS's ROE of +0.11%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ABCAPITAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABCAPITAL.NS's competition here
PRISMMEDI.BO vs AIIL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, AIIL.BO has a market cap of 429.6B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while AIIL.BO trades at ₹507.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas AIIL.BO's P/E ratio is 11.82. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to AIIL.BO's ROE of +0.25%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AIIL.BO's competition here
PRISMMEDI.BO vs PEL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, PEL.BO has a market cap of 254.9B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while PEL.BO trades at ₹1,124.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas PEL.BO's P/E ratio is 44.24. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to PEL.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to PEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check PEL.BO's competition here
PRISMMEDI.BO vs INDIGRID-IV.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, INDIGRID-IV.NS has a market cap of 156.5B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while INDIGRID-IV.NS trades at ₹164.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas INDIGRID-IV.NS's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to INDIGRID-IV.NS's ROE of +0.06%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INDIGRID-IV.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDIGRID-IV.NS's competition here
PRISMMEDI.BO vs INDIGRID.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, INDIGRID.NS has a market cap of 118.7B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while INDIGRID.NS trades at ₹164.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas INDIGRID.NS's P/E ratio is 42.20. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to INDIGRID.NS's ROE of +0.06%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INDIGRID.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDIGRID.NS's competition here
PRISMMEDI.BO vs ELCIDIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ELCIDIN.BO has a market cap of 22B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ELCIDIN.BO trades at ₹111,200.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ELCIDIN.BO's P/E ratio is 16.93. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ELCIDIN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ELCIDIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ELCIDIN.BO's competition here
PRISMMEDI.BO vs ZSARACOM.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ZSARACOM.BO has a market cap of 12.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ZSARACOM.BO trades at ₹11,800.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ZSARACOM.BO's P/E ratio is 49.03. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ZSARACOM.BO's ROE of +0.09%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ZSARACOM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ZSARACOM.BO's competition here
PRISMMEDI.BO vs CENTRUM.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CENTRUM.BO has a market cap of 11.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CENTRUM.BO trades at ₹24.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CENTRUM.BO's P/E ratio is -8.36. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CENTRUM.BO's ROE of -0.17%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CENTRUM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CENTRUM.BO's competition here
PRISMMEDI.BO vs CENTRUM.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CENTRUM.NS has a market cap of 11.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CENTRUM.NS trades at ₹24.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CENTRUM.NS's P/E ratio is -8.32. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CENTRUM.NS's ROE of -0.17%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CENTRUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CENTRUM.NS's competition here
PRISMMEDI.BO vs CREST.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CREST.NS has a market cap of 9.6B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CREST.NS trades at ₹349.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CREST.NS's P/E ratio is 19.34. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CREST.NS's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CREST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CREST.NS's competition here
PRISMMEDI.BO vs CREST.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CREST.BO has a market cap of 9.6B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CREST.BO trades at ₹349.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CREST.BO's P/E ratio is 18.96. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CREST.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CREST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CREST.BO's competition here
PRISMMEDI.BO vs RELCAPITAL.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, RELCAPITAL.NS has a market cap of 3.1B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while RELCAPITAL.NS trades at ₹12.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas RELCAPITAL.NS's P/E ratio is -0.25. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to RELCAPITAL.NS's ROE of -0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to RELCAPITAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check RELCAPITAL.NS's competition here
PRISMMEDI.BO vs IVC.NS Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, IVC.NS has a market cap of 2.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while IVC.NS trades at ₹7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas IVC.NS's P/E ratio is 17.93. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to IVC.NS's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to IVC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check IVC.NS's competition here
PRISMMEDI.BO vs IVC.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, IVC.BO has a market cap of 2.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while IVC.BO trades at ₹7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas IVC.BO's P/E ratio is 17.88. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to IVC.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to IVC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check IVC.BO's competition here
PRISMMEDI.BO vs YASTF.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, YASTF.BO has a market cap of 1.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while YASTF.BO trades at ₹136.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas YASTF.BO's P/E ratio is 174.27. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to YASTF.BO's ROE of +0.26%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to YASTF.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check YASTF.BO's competition here
PRISMMEDI.BO vs ABVL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ABVL.BO has a market cap of 1.4B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ABVL.BO trades at ₹7.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ABVL.BO's P/E ratio is -82.44. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ABVL.BO's ROE of -0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ABVL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ABVL.BO's competition here
PRISMMEDI.BO vs INTELLCAP.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, INTELLCAP.BO has a market cap of 1.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while INTELLCAP.BO trades at ₹45.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas INTELLCAP.BO's P/E ratio is 1097.56. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to INTELLCAP.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INTELLCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INTELLCAP.BO's competition here
PRISMMEDI.BO vs GLOBUSCON.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GLOBUSCON.BO has a market cap of 1.3B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GLOBUSCON.BO trades at ₹12.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GLOBUSCON.BO's P/E ratio is 41.39. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GLOBUSCON.BO's ROE of +0.53%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GLOBUSCON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GLOBUSCON.BO's competition here
PRISMMEDI.BO vs RSDFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, RSDFIN.BO has a market cap of 1.2B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while RSDFIN.BO trades at ₹99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas RSDFIN.BO's P/E ratio is 12.98. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to RSDFIN.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to RSDFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check RSDFIN.BO's competition here
PRISMMEDI.BO vs AGVENTURES.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, AGVENTURES.BO has a market cap of 1.2B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while AGVENTURES.BO trades at ₹115.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas AGVENTURES.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to AGVENTURES.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AGVENTURES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AGVENTURES.BO's competition here
PRISMMEDI.BO vs ZMILGFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ZMILGFIN.BO has a market cap of 1B. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ZMILGFIN.BO trades at ₹59.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ZMILGFIN.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ZMILGFIN.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to ZMILGFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ZMILGFIN.BO's competition here
PRISMMEDI.BO vs FERVENTSYN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, FERVENTSYN.BO has a market cap of 985.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while FERVENTSYN.BO trades at ₹20.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas FERVENTSYN.BO's P/E ratio is 31.79. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to FERVENTSYN.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to FERVENTSYN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check FERVENTSYN.BO's competition here
PRISMMEDI.BO vs YAMNINV.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, YAMNINV.BO has a market cap of 772.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while YAMNINV.BO trades at ₹0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas YAMNINV.BO's P/E ratio is -14.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to YAMNINV.BO's ROE of -0.03%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to YAMNINV.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check YAMNINV.BO's competition here
PRISMMEDI.BO vs APOORVA.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, APOORVA.BO has a market cap of 722.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while APOORVA.BO trades at ₹36.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas APOORVA.BO's P/E ratio is -361.70. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to APOORVA.BO's ROE of -0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to APOORVA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check APOORVA.BO's competition here
PRISMMEDI.BO vs REGIS.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, REGIS.BO has a market cap of 665.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while REGIS.BO trades at ₹2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas REGIS.BO's P/E ratio is 25.80. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to REGIS.BO's ROE of +0.08%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to REGIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check REGIS.BO's competition here
PRISMMEDI.BO vs MORGAN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MORGAN.BO has a market cap of 587.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MORGAN.BO trades at ₹58.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MORGAN.BO's P/E ratio is 2.66. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MORGAN.BO's ROE of +0.10%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MORGAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MORGAN.BO's competition here
PRISMMEDI.BO vs TOYAMSL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, TOYAMSL.BO has a market cap of 566.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while TOYAMSL.BO trades at ₹0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas TOYAMSL.BO's P/E ratio is -1.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to TOYAMSL.BO's ROE of -0.18%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to TOYAMSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TOYAMSL.BO's competition here
PRISMMEDI.BO vs NCLRESE.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, NCLRESE.BO has a market cap of 481.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while NCLRESE.BO trades at ₹0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas NCLRESE.BO's P/E ratio is 15.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to NCLRESE.BO's ROE of +0.03%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to NCLRESE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check NCLRESE.BO's competition here
PRISMMEDI.BO vs LERTHAI.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, LERTHAI.BO has a market cap of 408M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while LERTHAI.BO trades at ₹569.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas LERTHAI.BO's P/E ratio is -165.10. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to LERTHAI.BO's ROE of -0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to LERTHAI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check LERTHAI.BO's competition here
PRISMMEDI.BO vs OASISEC.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, OASISEC.BO has a market cap of 352.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while OASISEC.BO trades at ₹18.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas OASISEC.BO's P/E ratio is 35.26. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to OASISEC.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to OASISEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check OASISEC.BO's competition here
PRISMMEDI.BO vs MIL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MIL.BO has a market cap of 330.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MIL.BO trades at ₹33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MIL.BO's P/E ratio is 3304.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MIL.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MIL.BO's competition here
PRISMMEDI.BO vs KKFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, KKFIN.BO has a market cap of 329.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while KKFIN.BO trades at ₹58.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas KKFIN.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to KKFIN.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to KKFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KKFIN.BO's competition here
PRISMMEDI.BO vs MONOT.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MONOT.BO has a market cap of 323.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MONOT.BO trades at ₹0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MONOT.BO's P/E ratio is 4.60. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MONOT.BO's ROE of -1.74%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MONOT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MONOT.BO's competition here
PRISMMEDI.BO vs KARTKIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, KARTKIN.BO has a market cap of 306.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while KARTKIN.BO trades at ₹1,256.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas KARTKIN.BO's P/E ratio is 6.04. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to KARTKIN.BO's ROE of N/A. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to KARTKIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KARTKIN.BO's competition here
PRISMMEDI.BO vs JOHNPHARMA.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, JOHNPHARMA.BO has a market cap of 302.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while JOHNPHARMA.BO trades at ₹0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas JOHNPHARMA.BO's P/E ratio is -55.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to JOHNPHARMA.BO's ROE of -0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to JOHNPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check JOHNPHARMA.BO's competition here
PRISMMEDI.BO vs QGO.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, QGO.BO has a market cap of 296.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while QGO.BO trades at ₹39.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas QGO.BO's P/E ratio is 9.29. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to QGO.BO's ROE of +0.18%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to QGO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check QGO.BO's competition here
PRISMMEDI.BO vs TCFCFINQ.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, TCFCFINQ.BO has a market cap of 295.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while TCFCFINQ.BO trades at ₹27.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas TCFCFINQ.BO's P/E ratio is 134.43. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to TCFCFINQ.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to TCFCFINQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TCFCFINQ.BO's competition here
PRISMMEDI.BO vs MARGOFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MARGOFIN.BO has a market cap of 286.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MARGOFIN.BO trades at ₹63.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MARGOFIN.BO's P/E ratio is 184.65. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MARGOFIN.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MARGOFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MARGOFIN.BO's competition here
PRISMMEDI.BO vs MORARKFI.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MORARKFI.BO has a market cap of 278.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MORARKFI.BO trades at ₹61.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MORARKFI.BO's P/E ratio is 14.97. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MORARKFI.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MORARKFI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MORARKFI.BO's competition here
PRISMMEDI.BO vs BOMTALKIES.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, BOMTALKIES.BO has a market cap of 275.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while BOMTALKIES.BO trades at ₹4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas BOMTALKIES.BO's P/E ratio is -170.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to BOMTALKIES.BO's ROE of -0.04%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BOMTALKIES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BOMTALKIES.BO's competition here
PRISMMEDI.BO vs INDCEMCAP.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, INDCEMCAP.BO has a market cap of 262M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while INDCEMCAP.BO trades at ₹12.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas INDCEMCAP.BO's P/E ratio is 150.88. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to INDCEMCAP.BO's ROE of -0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INDCEMCAP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INDCEMCAP.BO's competition here
PRISMMEDI.BO vs EASUN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, EASUN.BO has a market cap of 257.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while EASUN.BO trades at ₹49.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas EASUN.BO's P/E ratio is 87.93. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to EASUN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to EASUN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check EASUN.BO's competition here
PRISMMEDI.BO vs STRLGUA.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, STRLGUA.BO has a market cap of 255M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while STRLGUA.BO trades at ₹39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas STRLGUA.BO's P/E ratio is -136.84. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to STRLGUA.BO's ROE of +0.09%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to STRLGUA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check STRLGUA.BO's competition here
PRISMMEDI.BO vs SWRNASE.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, SWRNASE.BO has a market cap of 244.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while SWRNASE.BO trades at ₹85.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas SWRNASE.BO's P/E ratio is 30.79. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to SWRNASE.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to SWRNASE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SWRNASE.BO's competition here
PRISMMEDI.BO vs HRMNYCP.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, HRMNYCP.BO has a market cap of 241.6M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while HRMNYCP.BO trades at ₹80.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas HRMNYCP.BO's P/E ratio is -66.55. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to HRMNYCP.BO's ROE of -0.45%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to HRMNYCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check HRMNYCP.BO's competition here
PRISMMEDI.BO vs SOUTLAT.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, SOUTLAT.BO has a market cap of 237.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while SOUTLAT.BO trades at ₹31.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas SOUTLAT.BO's P/E ratio is 94.91. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to SOUTLAT.BO's ROE of +0.04%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to SOUTLAT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SOUTLAT.BO's competition here
PRISMMEDI.BO vs INVIGO.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, INVIGO.BO has a market cap of 233.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while INVIGO.BO trades at ₹5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas INVIGO.BO's P/E ratio is -96.67. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to INVIGO.BO's ROE of +0.00%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to INVIGO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check INVIGO.BO's competition here
PRISMMEDI.BO vs GLOBALCA.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GLOBALCA.BO has a market cap of 215.1M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GLOBALCA.BO trades at ₹0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GLOBALCA.BO's P/E ratio is 18.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GLOBALCA.BO's ROE of +0.03%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GLOBALCA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GLOBALCA.BO's competition here
PRISMMEDI.BO vs PRESSURS.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, PRESSURS.BO has a market cap of 195.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while PRESSURS.BO trades at ₹1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas PRESSURS.BO's P/E ratio is 0.18. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to PRESSURS.BO's ROE of -0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to PRESSURS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check PRESSURS.BO's competition here
PRISMMEDI.BO vs SHYMINV.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, SHYMINV.BO has a market cap of 180.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while SHYMINV.BO trades at ₹12.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas SHYMINV.BO's P/E ratio is 18.29. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to SHYMINV.BO's ROE of +0.12%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to SHYMINV.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYMINV.BO's competition here
PRISMMEDI.BO vs GSLSEC.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GSLSEC.BO has a market cap of 180.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GSLSEC.BO trades at ₹55.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GSLSEC.BO's P/E ratio is -57.58. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GSLSEC.BO's ROE of -0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GSLSEC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GSLSEC.BO's competition here
PRISMMEDI.BO vs CHITRTX.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CHITRTX.BO has a market cap of 174.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CHITRTX.BO trades at ₹119.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CHITRTX.BO's P/E ratio is -52.92. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CHITRTX.BO's ROE of -0.08%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to CHITRTX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CHITRTX.BO's competition here
PRISMMEDI.BO vs DFL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, DFL.BO has a market cap of 150.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while DFL.BO trades at ₹42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas DFL.BO's P/E ratio is 67.19. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to DFL.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to DFL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check DFL.BO's competition here
PRISMMEDI.BO vs TOKYOFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, TOKYOFIN.BO has a market cap of 149.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while TOKYOFIN.BO trades at ₹21.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas TOKYOFIN.BO's P/E ratio is 358.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to TOKYOFIN.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to TOKYOFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check TOKYOFIN.BO's competition here
PRISMMEDI.BO vs CITL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, CITL.BO has a market cap of 147.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while CITL.BO trades at ₹0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas CITL.BO's P/E ratio is -1.10. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to CITL.BO's ROE of +0.16%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to CITL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check CITL.BO's competition here
PRISMMEDI.BO vs GARBIFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GARBIFIN.BO has a market cap of 146.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GARBIFIN.BO trades at ₹12.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GARBIFIN.BO's P/E ratio is 21.57. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GARBIFIN.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GARBIFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GARBIFIN.BO's competition here
PRISMMEDI.BO vs MINOLTAF.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MINOLTAF.BO has a market cap of 133M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MINOLTAF.BO trades at ₹1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MINOLTAF.BO's P/E ratio is -2.37. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MINOLTAF.BO's ROE of -0.36%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MINOLTAF.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MINOLTAF.BO's competition here
PRISMMEDI.BO vs ECSTSTL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, ECSTSTL.BO has a market cap of 106.7M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while ECSTSTL.BO trades at ₹20.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas ECSTSTL.BO's P/E ratio is 17.19. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to ECSTSTL.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to ECSTSTL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check ECSTSTL.BO's competition here
PRISMMEDI.BO vs GALADAFIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GALADAFIN.BO has a market cap of 91.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GALADAFIN.BO trades at ₹31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GALADAFIN.BO's P/E ratio is 24.76. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GALADAFIN.BO's ROE of +0.06%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GALADAFIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GALADAFIN.BO's competition here
PRISMMEDI.BO vs JAYBHCR.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, JAYBHCR.BO has a market cap of 83.3M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while JAYBHCR.BO trades at ₹16.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas JAYBHCR.BO's P/E ratio is -7.71. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to JAYBHCR.BO's ROE of +0.02%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to JAYBHCR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check JAYBHCR.BO's competition here
PRISMMEDI.BO vs AGARWAL.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, AGARWAL.BO has a market cap of 76.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while AGARWAL.BO trades at ₹22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas AGARWAL.BO's P/E ratio is 42.81. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to AGARWAL.BO's ROE of +0.34%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AGARWAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AGARWAL.BO's competition here
PRISMMEDI.BO vs MFSINTRCRP.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MFSINTRCRP.BO has a market cap of 71.4M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MFSINTRCRP.BO trades at ₹15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MFSINTRCRP.BO's P/E ratio is -35.87. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MFSINTRCRP.BO's ROE of -0.18%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to MFSINTRCRP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MFSINTRCRP.BO's competition here
PRISMMEDI.BO vs MLINDLTD.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MLINDLTD.BO has a market cap of 62.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MLINDLTD.BO trades at ₹10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MLINDLTD.BO's P/E ratio is 10.34. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MLINDLTD.BO's ROE of +0.07%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MLINDLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MLINDLTD.BO's competition here
PRISMMEDI.BO vs GANHOLD.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, GANHOLD.BO has a market cap of 61.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while GANHOLD.BO trades at ₹70.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas GANHOLD.BO's P/E ratio is -26.64. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to GANHOLD.BO's ROE of -0.07%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to GANHOLD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check GANHOLD.BO's competition here
PRISMMEDI.BO vs AMERISE.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, AMERISE.BO has a market cap of 48.9M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while AMERISE.BO trades at ₹0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas AMERISE.BO's P/E ratio is 74.00. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to AMERISE.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to AMERISE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check AMERISE.BO's competition here
PRISMMEDI.BO vs MAHANIN.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, MAHANIN.BO has a market cap of 43.2M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while MAHANIN.BO trades at ₹9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas MAHANIN.BO's P/E ratio is -106.56. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to MAHANIN.BO's ROE of -0.02%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to MAHANIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check MAHANIN.BO's competition here
PRISMMEDI.BO vs KUBERJI.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, KUBERJI.BO has a market cap of 39.5M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while KUBERJI.BO trades at ₹12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas KUBERJI.BO's P/E ratio is 19.17. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to KUBERJI.BO's ROE of +0.05%. Regarding short-term risk, PRISMMEDI.BO is less volatile compared to KUBERJI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check KUBERJI.BO's competition here
PRISMMEDI.BO vs BEEYU.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, BEEYU.BO has a market cap of 37.8M. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while BEEYU.BO trades at ₹2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas BEEYU.BO's P/E ratio is -44.50. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to BEEYU.BO's ROE of -0.08%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to BEEYU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check BEEYU.BO's competition here
PRISMMEDI.BO vs SHYAM.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, SHYAM.BO has a market cap of 0. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while SHYAM.BO trades at ₹8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas SHYAM.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to SHYAM.BO's ROE of N/A. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to SHYAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYAM.BO's competition here
PRISMMEDI.BO vs SHYAMAINFO.BO Comparison February 2026
PRISMMEDI.BO plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRISMMEDI.BO stands at 136.9M. In comparison, SHYAMAINFO.BO has a market cap of 0. Regarding current trading prices, PRISMMEDI.BO is priced at ₹20.53, while SHYAMAINFO.BO trades at ₹7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRISMMEDI.BO currently has a P/E ratio of -322.57, whereas SHYAMAINFO.BO's P/E ratio is N/A. In terms of profitability, PRISMMEDI.BO's ROE is +0.04%, compared to SHYAMAINFO.BO's ROE of +0.01%. Regarding short-term risk, PRISMMEDI.BO is more volatile compared to SHYAMAINFO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PRISMMEDI.BO.Check SHYAMAINFO.BO's competition here